JP2022516662A5 - - Google Patents

Info

Publication number
JP2022516662A5
JP2022516662A5 JP2021539637A JP2021539637A JP2022516662A5 JP 2022516662 A5 JP2022516662 A5 JP 2022516662A5 JP 2021539637 A JP2021539637 A JP 2021539637A JP 2021539637 A JP2021539637 A JP 2021539637A JP 2022516662 A5 JP2022516662 A5 JP 2022516662A5
Authority
JP
Japan
Prior art keywords
compound
individual
pharmaceutical composition
solvate
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021539637A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516662A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012783 external-priority patent/WO2020146529A1/en
Publication of JP2022516662A publication Critical patent/JP2022516662A/ja
Publication of JP2022516662A5 publication Critical patent/JP2022516662A5/ja
Ceased legal-status Critical Current

Links

JP2021539637A 2019-01-08 2020-01-08 S1p1受容体に関連する状態を治療する方法 Ceased JP2022516662A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789937P 2019-01-08 2019-01-08
US62/789,937 2019-01-08
PCT/US2020/012783 WO2020146529A1 (en) 2019-01-08 2020-01-08 Methods of treating conditions related to the s1p1 receptor

Publications (2)

Publication Number Publication Date
JP2022516662A JP2022516662A (ja) 2022-03-01
JP2022516662A5 true JP2022516662A5 (cg-RX-API-DMAC7.html) 2023-01-20

Family

ID=69467760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539637A Ceased JP2022516662A (ja) 2019-01-08 2020-01-08 S1p1受容体に関連する状態を治療する方法

Country Status (10)

Country Link
US (1) US20220142977A1 (cg-RX-API-DMAC7.html)
EP (1) EP3908276B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022516662A (cg-RX-API-DMAC7.html)
KR (1) KR102958419B1 (cg-RX-API-DMAC7.html)
CN (2) CN113874009A (cg-RX-API-DMAC7.html)
AU (1) AU2020206700A1 (cg-RX-API-DMAC7.html)
CA (1) CA3124701A1 (cg-RX-API-DMAC7.html)
IL (1) IL284114A (cg-RX-API-DMAC7.html)
MX (1) MX2021008263A (cg-RX-API-DMAC7.html)
WO (1) WO2020146529A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
KR20190113955A (ko) 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連する状態を治療する方法
ES2951870T3 (es) * 2018-10-03 2023-10-25 Arena Pharm Inc Etrasimod para su uso en procedimientos para el tratamiento de la esclerodermia
MX2021008263A (es) 2019-01-08 2021-10-13 Arena Pharm Inc Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
WO2025177319A2 (en) * 2024-02-22 2025-08-28 Msn Laboratories Private Limited, R&D Center Solid state forms of L-Arginine, (3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopent[b]indole-3-acetate and processes for preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104311472B9 (zh) 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
PL2342205T4 (pl) * 2008-08-27 2016-12-30 Podstawione tricykliczne pochodne kwasowe jako antagoniści receptora S1P1 użyteczni w leczeniu zaburzeń autoimmunologicznych i zapalnych
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および/または治療のための宿主防御タンパク質(hdp)模倣薬
MX2021008263A (es) 2019-01-08 2021-10-13 Arena Pharm Inc Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.

Similar Documents

Publication Publication Date Title
JP2505944B2 (ja) (S)―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物
JP4938905B2 (ja) 選択的s1p1レセプターアゴニストの投与法
CN111132675B (zh) 胆汁淤积性瘙痒的治疗
KR101801864B1 (ko) 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
US20170216212A1 (en) Tapentadol compositions
JP2022511788A5 (cg-RX-API-DMAC7.html)
AU2009242113A1 (en) Combination compositions for treating Alzheimer disease and related disorders with zonisamide and acamprosate
JP5208473B2 (ja) アゼラスチンと抗コリン薬を含有する医薬組成物
JP2022550919A5 (cg-RX-API-DMAC7.html)
CN1210465A (zh) 治疗方法和药物组合物
WO2005094832A1 (en) Compositions comprising meloxicam
JP2023509698A5 (cg-RX-API-DMAC7.html)
CN115702143A (zh) 治疗系统性硬化症的方法
WO2021207349A1 (en) Prevention and treatment of virial infections
JP2026510948A (ja) 慢性閉塞性肺疾患患者におけるエンテロウイルスの治療方法
TWI282735B (en) Combination and pharmaceutical formulation for the treatment of HBV infection
JP4384435B2 (ja) くしゃみ抑制組成物
WO2018232260A1 (en) Methods and compositions to inhibit symptoms associated with viral upper respiratory tract infections
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
CN1263465A (zh) 利用选择性5-羟色胺再摄取抑制剂治疗和预防心脏病
RU2021123406A (ru) Способы лечения состояний, связанных с рецептором s1p1
JPWO2005063253A1 (ja) アレルギー症状治療用医薬組成物
JP2009007332A (ja) アゼラスチン類とエフェドリン類を含有する医薬組成物
JP2010111667A (ja) フェキソフェナジン又はエバスチンを含有する鎮咳及び/又は去痰のための医薬組成物
JPH04282313A (ja) 血圧降下剤